Allergy Therapeutics (AGY)
AGY Share PerformanceMore
|52 week high||39.50 10/10/17|
|52 week low||19.50 12/12/16|
|52 week change||9.13 (42.20%)|
|4 week volume||4,474,515 23/10/17|
Latest News« previous» nextMore
13/11/2017 - 07:00 RNS
RNS Number: 2495W Allergy Therapeutics PLC 13 November 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Allergy Therapeutics to Present at Jefferies 2017 London Healthcare Conference 13 November 2017 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announces th...
07/11/2017 - 12:59 RNS
RNS Number: 8138V Allergy Therapeutics PLC 07 November 2017 The announcement released by Allergy Therapeutics plcentitled "Director/ PDMR Shareholding" on 7 November 2017 at 11:54 incorrectly stated the exercise price as 0.0001 per share. The correct exercise price is 0.001. All other figures remain unchanged. The correct figure is included in the reissued ann...
07/11/2017 - 11:54 RNS
RNS Number: 8006V Allergy Therapeutics PLC 07 November 2017 07 November 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Company") Grant of Options under Long Term Incentive Plan Allergy Therapeutics (AIM:AGY) , the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces that certain performance c...
19/10/2017 - 15:14 RNS
RNS Number: 1267U Allergy Therapeutics PLC 19 October 2017 19 October 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Company") ANNUAL FINANCIAL REPORT 2017 AND NOTICE OF 2017 ANNUAL GENERAL MEETING Allergy Therapeutics Plc has today published the following documents: Annual Report for the year ended 30 June 201...
19/10/2017 - 08:52 StockMarketWire
Allergy Therapeutics has started its G205 phase II study designed to evaluate the dose-response and safety of its ultra-short c...
19/10/2017 - 06:00 RNS
RNS Number: 0102U Allergy Therapeutics PLC 19 October 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Commencement of dosing in PQ Grass Phase II Trial 19 October 2017 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, today announces that dosing has commenced i...
12/10/2017 - 16:39 RNS
RNS Number: 4959T Allergy Therapeutics PLC 12 October 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Allergy The...
12/10/2017 - 14:20 StockMarketWire
Dr Tunde Otulana, Non Executive Director, bought 25,000 shares in the company on the 11th October 2017 at a price of 38.4...
|Dividend yield||0 %|
Latest discussion posts More
“Interesting article on p8 of Daily Telegraph today. Year long trial using patches (not injections like AGY). 50% of those wearing the strongest dosage patches experienced a ...”▼
“Harman although I like the sound of Hardpan Research. I could have done with some of that many times in investments made!!”▼
“Excellent volume today. The hardpan research or maybe AGY is beginning to be noticed with its excellent product and product pipeline. CL”▼
Codes & Symbols
|Symbols||AGY, LSE:AGY, AGY.L, AGY:LN, LON:AGY, XLON:AGY|
Join interactive investor
- £22.50 fixed quarterly charge includes £22.50 in trading credits
- £10 per trade or £6 for frequent traders
- No % platform fees
- £1 per trade for regular investment or dividend reinvestment